- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- Biotin: Interference with Laboratory Assays
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- CardioIQ® Insulin Resistance Panel with Score
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Diagnosis of Intestinal Parasites
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metabolite, with Confirmation, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Familial Hypercholesterolemia (FH) Panel
- Familial Hypercholesterolemia (FH) Single Site
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- HCV Genotyping
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis B Surface Antigen, Quantitative, Monitoring
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C Virus Antibody and RNA Testing
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1 Resistance, Proviral DNA (RTI, PI, Integrase Inhibitors)
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Infliximab and Adalimumab Drug and Anti-drug Antibody Testing
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Pain Management and CYP2D6/CYP2C19
- Pain Management Antidepressants, With Confirmation, Urine
- Pain Management Antipsychotics, With Confirmation, Serum and Urine
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- PIK3CA Mutation Analysis
- Platelet Antibody Screen (Indirect)
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
Cardio IQ® Lipoprotein Fractionation, Ion MobilityTest code(s) 91604, 94220, 92145
Question 1. What is ion mobility lipoprotein fractionation?
Ion mobility lipoprotein fractionation is a technology that uses gas-phase (laminar flow) electrophoresis to separate unmodified lipoproteins on the basis of size. Following the separation, each lipoprotein particle is directly detected and counted as it exits the separation chamber.
Ion mobility fractionation provides direct measurement of lipid subclasses. This approach to advanced lipid testing combines high-resolution separation of the full spectrum of lipoprotein particles with direct quantitation of particles in each lipoprotein subclass.
The sizes of the lipoprotein particles detected and counted are not affected by particle modifications. The particles are unaltered by stains or ultracentrifugation forces. Ionized lipoprotein particles are electrophoretically separated in a gas phase, and lipoprotein particles are distinguished on the basis of size. Size-separated particles are detected and counted by light scattering.
Ionized lipoproteins migrate across a laminar gas-phase flow, based on size and electrical field. Only a single size of lipoprotein will exit the field and be isolated (green line) at any point across the voltage gradient; larger and smaller lipoproteins (dotted black) are not collected. As the voltage ramps across the gradient, all of the lipoproteins are captured.
The high resolution of ion mobility’s lipoprotein subfractionation is comparable to that seen with analytical ultracentrifugation (AnUC) and segmented gradient gel electrophoresis (SGGE) methods.1 Thus, the extensive literature supporting the clinical use of lipoprotein subclasses derived from these 2 methods can be applied to ion mobility-derived subclasses as well.
Question 2. What is the clinical utility of lipoprotein fractionation using ion mobility?
Advanced lipid testing with Ion Mobility is used to help assess the risk for cardiovascular disease (CVD) in patients with intermediate or high risk based on traditional or emerging risk factors, and to assess therapeutic response in patients undergoing lipid-lowering therapy.
Question 3. Which lipoprotein subclasses are reported and what do the results mean for the patient’s risk for CVD?
Ion mobility technology precisely quantifies lipoprotein fractions across the entire lipoprotein spectrum; this comprises very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particles.1 However, to facilitate risk assessment, Quest Diagnostics reports only those measurements that were significantly correlated with CVD events in a cohort of men and women from the prospective Malmo Diet and Cancer Study2:
- Small, medium, and total LDL particle numbers (p≤0.004)2,3
- LDL peak size (p≤0.012) and the associated LDL pattern2,3
- Large HDL particle number (p<0.001)2
The focus on these measurements, which include increased triglycerides, is consistent with identification of the “atherogenic lipoprotein phenotype” first proposed in 1990.4,5
An elevated total LDL particle number is associated with a 1.2 to 1.4-fold increase in CVD risk.2,3 Similarly, elevated small and medium LDL particle numbers have been associated with a 1.2 to 1.4-fold increase.2,3
Ion mobility identifies 2 main subclasses of HDL: large HDL and small HDL. The antioxidant properties of large HDL may help protect the arterial wall. A decreased large HDL subclass has historically suggested increased CVD risk.
Question 4. How do the ion mobility and nuclear magnetic resonance technologies compare?
The ion mobility-derived total, small, and medium LDL subclass concentrations (nmol/L) reflect direct detection and quantitation of the number of LDL particles.1
In contrast, the nuclear magnetic resonance (NMR)-derived LDL particle number (LDL-P, nmol/L) includes the 3 LDL subclasses (small, medium, total LDL) and IDL. The concentration is measured indirectly from NMR signals emanating from terminal methyl groups from all different lipid classes (triglycerides, cholesterol ester, unesterified cholesterol and phospholipids) in the lipoprotein particle shell and core.6
Question 5. How does the ion mobility-derived total LDL particle measurement compare to an apolipoprotein B measurement?
As noted above, the ion mobility-derived total LDL particle concentration (nmol/L) reflects direct detection and quantitation of the total number of LDL particles.1
Apolipoprotein B (apo B) measurements, on the other hand, represent the number of non-HDL particles, including LDL particles. Commercially available apo B assays measure lipoproteins containing apo B-100 and apo B-48. This includes the apo B component of LDL, IDL, VLDL, lipoprotein(a), and chylomicrons. Results are reported as mg/dL.
Question 6. How should discrepant LDL phenotype, LDL particle size, total LDL particle number, and LDL subclass results be interpreted?
All results from risk markers should be considered when assessing a person’s risk for CVD, even when they place the person in different risk categories. This is especially important when assessing residual risk.
That being said, it is reasonable that the finer the measuring tool and the more specific the data being generated, the more insightful the conclusions may be. Historically, LDL subclass patterns (ie, phenotype) have been characterized as predominantly small and dense (LDL pattern B) or predominantly large and buoyant (LDL pattern A) in order to characterize populations for analysis in research studies. However, some patients classified as having LDL pattern A can have an unhealthy amount of small LDL.
The LDL particle size is the diameter at the maximum LDL peak height and is a good general measure of the LDL particle distribution. However, it does not always accurately reflect particle distribution.
A high total LDL particle number may be the result of a high number of large LDL particles or a high number of small LDL particles. All LDL particles are atherogenic, but the small LDL particles are considered to be more atherogenic. Thus, knowledge of the individual LDL subclass contribution to the total LDL particle number helps the clinician interpret the total LDL particle number result.
Question 7. How are the optimal (O), moderate (M), and high (H) risk categories shown for Cardio IQ Ion Mobility determined?
The lipoprotein subfraction reference intervals and cut-points for ion mobility were generated primarily from 2 large, well-known clinical cohort populations of men and women.7,8 The data derived from these studies were used to represent the population typically tested for CVD risk and to establish the reference intervals for the lipoprotein subfractions. The optimal (O), moderate (M), and high (H) risk categories shown on the report for a select group of lipoprotein subclasses were established at the tertile cut-points of the combined populations.
Question 8. How are ion mobility-derived results incorporated into an overall risk assessment?
When assessing a person’s risk for CVD, all results from risk markers should be considered, even when they place the person in different risk categories. This is especially important when assessing residual risk. Below is an example that demonstrates the importance of considering multiple ion mobility-derived risk markers.
Pattern A is classified as optimal, and pattern B is classified as high-risk. This is based on large population studies showing that people without coronary heart disease tend to have an abundance of large, buoyant LDL particles (pattern A), and people with coronary heart disease tend to have an abundance of smaller, dense LDL particles (pattern B).5
However, the literature suggests that CVD risk is conferred by a trio of factors that define the atherogenic lipoprotein profile (ALP).9 The ALP includes elevated small LDL particles (pattern B), low levels of HDL-cholesterol, and often an elevated fasting triglyceride concentration. Thus, the LDL pattern phenotype is only one aspect of the ALP. Additionally, neither the LDL pattern phenotype nor the ALP reflects risk associated with HDL subclasses or the number of small LDL particles. For an example of how LDL particle number can contribute to the overall CVD risk assessment, consider a patient with an optimal pattern A LDL phenotype and a high total LDL mass. If the number of small LDL particles is also high, the patient may be at increased risk despite the favorable pattern A result. Thus, quantitating lipoprotein subclasses (ie, small, medium) can provide important information when assessing overall CVD risk. Interpreting the favorable pattern A result as indicative of low CVD risk could mistakenly rule out treatment in a patient who could benefit from it.
Question 9. Why do you use ångström units in the Cardio IQ report?
The ångström (Å) (0.1 nm) is a unit of measure denoting the diameter (size) of a particle. This diameter is used to determine the pattern A vs pattern B LDL phenotype.
The Cardio IQ report shows the particle diameter on the horizontal axis of the lipoprotein fractionation graphical display. The ångström measurement at the apex of the major LDL lipoprotein peak is reported in both the summary results table and the ion mobility detail table, labeled as LDL Peak Size.
- Caulfield MP, Li S, Lee G, et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem. 2008;54:1307-1316.
- Musunuru K, Orho-Melander M, Caulfield M, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol. 2009;29:1975-1980.
- Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high intensity statin or placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation. 2015;132:2220-2229.
- Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
- Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation. 2009;119:2383-2395.
- Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:1735-1741.
- Berglund G, Nilsson P, Eriksson K-F et al. Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. J Intern Med. 2000;247:19–29.
- Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-878.
- Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21:305–311.